News & insights

Advertising Quarterly Q4 2024: Legal, regulatory and other developments

by Louise Popple and Charlie Barraud

Orphan drug protection: clarification needed

by Dr Paul England

To use or not to use?

by Dr Paul England

Q4 2024: a visual guide to ASA rulings

by Kachenka Pribanova

FCA interviews influencers under caution

by Simon Jupp

Subscription contracts under the DMCC Act

by Oz Watson

Financial services matters - December 2024

by Martin Dowdall and Daniel Hirschfield

Beginner's guide to medicines advertising in Europe

Regulatory oversight in Europe strictly governs pharmaceutical advertising, including content, presentation, and audience, although with some variation between countries. Compliance with these regulations is essential to avoid sanctions and third-party damages claims.

by Nicholas Vollers

2 of 4 Insights

National penalties for breach of medical device advertising rules

Penalties for breaching advertising laws for medical devices or IVDs in Europe include administrative fines, criminal fines, and damages for unfair competition, but with huge variation between countries. Compliance with local laws is crucial to avoid sanctions and third party damages claims.

by multiple authors

3 of 4 Insights